Skip to main content
SpringerLink
Log in

Ophthalmika

  • Chapter
Arzneiverordnungs-Report 2015

  • 1926 Accesses

Zusammenfassung

Trend

Bei den Ophthalmika dominieren seit vielen Jahren die Glaukommittel, die neben den „klassischen“ Betarezeptorenblockern ganz überwiegend neuere Therapieprinzipien umfassen, wie selektive Alpha2-Agonisten, lokal wirkende Carboanhydrasehemmer und vor allem Prostaglandinderivate. Bei den meisten übrigen Gruppen von Ophthalmika sind die Verordnungen durch das GKV-Modernisierungsgesetz 2004 drastisch gesunken. Im Jahre 2014 sind die Verordnungen von Ophthalmika wiederum in fast allen Arzneimittelgruppen leicht angestiegen. Als Neuentwicklungen für die antineovaskuläre Therapie hat sich neben dem viel diskutierten antineovaskulären Antikörper Ranibizumab (Lucentis) mit dem Aflibercept (Eylea) ein weiterer VEGF-Antagonist unter den verordnungshäufigsten Arzneimitteln etabliert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • AGIS Investigators (2000): The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429–440

    Article  Google Scholar 

  • American Academy of Ophthalmology Retina/Vitreous Panel, Preferred Practice Pattern Guide- lines (2015): Age Related Macular degeneration. San Francisco, CA, 2015. Age-Related Macular Degeneration PPP - Updated 2015 (http://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015)

    Google Scholar 

  • Behrens-Baumann W, Begall T (1993): Antiseptics versus antibiotics in the treatment of the experimental conjunctivitis caused by staphylococcus aureus. Ger J Ophthalmol 2: 409–411

    CAS  PubMed  Google Scholar 

  • Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015): Comparison of ranibizumab and bevaci- zumab for neovascular age-related macular degeneration according to LUCAS treat-and- extend protocol. Ophthalmology 122: 146–152

    Article  PubMed  Google Scholar 

  • Bielory L (2002): Ocular allergy guidelines: a practical treatment algorithm. Drugs 62: 1611163–4

    Article  Google Scholar 

  • Bielory L, Lien KW, Bigelsen S (2005): Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 65: 215–228

    Article  CAS  PubMed  Google Scholar 

  • Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S (2011): Comparative role of intra- vitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age- related macular degeneration. Indian J Ophthalmol 59: 191–196

    Article  PubMed Central  PubMed  Google Scholar 

  • Bremond-Gignac D, Messaoud R, Lazreg S, Speeg-Schatz C, Renault D, Chiambaretta F (2015):

    Google Scholar 

  • A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness. Clin Ophthalmol 9: 725–732

    Google Scholar 

  • CATT Research Group (2011): Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Engl J Med 364: 1897–1908

    Article  Google Scholar 

  • Chalita MR, Hofling-Lima AL, Paranhos A Jr, Schor P, Belfort R Jr (2004): Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 137: 43–51

    Article  PubMed  Google Scholar 

  • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012): Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388–1398

    Article  PubMed  Google Scholar 

  • Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F (2009a): Pharmaco- therapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother 10: 2663–2677

    Article  CAS  PubMed  Google Scholar 

  • Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F (2009b): Pharmaco- therapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 10: 2859–2870

    Article  CAS  PubMed  Google Scholar 

  • Cvetkovic RS, Perry CM (2003): Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 20: 919–947

    Article  CAS  PubMed  Google Scholar 

  • Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC; IVAN Study Investigators (2014): Cost-effectiveness of ranibi- 35 zumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open 4: e00509–4

    Article  Google Scholar 

  • Danesh-Meyer HV (2011): Neuroprotection in glaucoma: recent and future directions. Curr Opin Ophthalmol 22: 78–86

    Article  PubMed  Google Scholar 

  • Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW (2015): Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372: 1193–1203

    Google Scholar 

  • Dietlein TS, Hermann MM, Jordan JF (2009): Medikamentöse und chirurgische Therapie des Glaukoms. Dtsch Ärztebl Int 106: 597–606

    PubMed Central  PubMed  Google Scholar 

  • Doughty MJ, Glavin S (2009): Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt 29: 573–583

    Article  PubMed  Google Scholar 

  • Elshout M, van der Reis MI, Webers CA, Schouten JS (2014): The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol 252: 1911–1920

    Article  CAS  PubMed  Google Scholar 

  • European Glaucoma Society: Terminology and guidelines for glaucoma. 4th Ed. (2014), DOGMA, Savona, Italien (http://www.eugs.org/eng/egs_guidelines_reg.asp7k!)

    Google Scholar 

  • Everett SL, Kowalski RP, Karenchak LM, Landsittel D, Day R, Gordon YL (1995): An in vitro com- parison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea 14: 382–387

    Article  CAS  PubMed  Google Scholar 

  • Everitt HA, Little PS, Smith PW (2006): A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. Brit med J 333: 321 Feiner L, Piltz-Seymour JR; Collaborative Initial Glaucoma Treatment Study (2003): Collabora- tive Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthal- mol 14: 106–111

    Google Scholar 

  • Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG (2015): Latanoprost for open-angle glaucoma (UKGTS): a randomised, multi- centre, placebo-controlled trial. Lancet 385: 1295–1304

    Article  CAS  PubMed  Google Scholar 

  • Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB (2010): Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab - a randomized controlled trial. Am J Ophthalmol 149: 458-464.e1

    Article  CAS  PubMed  Google Scholar 

  • Giardini F, Grandi G, De Sanctis U, Eandi C, Machetta F, Pollino C, Grignolo FM (2011): In vitro susceptibility to different topical ophthalmic antibiotics of bacterial isolates from patients with conjunctivitis. Ocul Immunol Inflamm 19: 419–421

    Article  CAS  PubMed  Google Scholar 

  • Göbbels M, Gross D (1996): Klinische Studie der Wirksamkeit einer Dexpanthenol-haltigen künstlichen Tränenflüssigkeit (Siccaprotect) bei der Behandlung des trockenen Auges. Klin Monatsbl Augenheilkd 209: 84–88

    Article  PubMed  Google Scholar 

  • Goldberg I (2002): Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy. Br J Ophthalmol 86: 691–692

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Goldberg I, Crowston JG, Jasek MC, Stewart JA, Stewart WC; ADAPT Study Investigator Group (2012): Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/>timolol fixed combination as adjunctive therapy. J Glaucoma 21: 55–59

    Article  Google Scholar 

  • Granet DB, Dorfman M, Stroman D, Cockrum P (2008): A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus 45: 340–349

    Article  PubMed  Google Scholar 

  • Grehn F (2008): Chirurgie des primären Offenwinkelglaukoms. Klin Monatsbl Augenheilkd 225: 30–38

    Article  CAS  PubMed  Google Scholar 

  • Greiner JV, Michaelson C, McWhirter CL, Shams NB (2002): Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. Adv Ther 19: 185–193

    Article  CAS  PubMed  Google Scholar 

  • Grieshaber MC, Flammer J (2010): Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance? - An exemplary analysis on the basis of two beta-blockers. Prog Retin Eye Res 29: 79–93

    Article  CAS  PubMed  Google Scholar 

  • Gunther JB, Altaweel MM (2009): Bevacizumab (avastin) for the treatment of ocular disease. Surv Ophthalmol 54: 372–400

    Article  PubMed  Google Scholar 

  • Haas W, Hesje CK, Sanfilippo CM, Morris TW (2011): High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis. Curr Eye Res 36: 1078–1085

    Article  CAS  PubMed  Google Scholar 

  • Hanioglu-Kargi S, Basci N, Soysal H, Bozkurt A, Gursel E, Kayaalp O (1998): The penetration of ofloxacin into human aqueous humor given by various routes. Eur J Ophthalmol 8: 33–36

    CAS  PubMed  Google Scholar 

  • Herkel U, Pfeiffer N (2001): Update on topical carbonic anhydrase inhibitors. Curr Opin Ophthalmol 12: 88–93

    Article  CAS  PubMed  Google Scholar 

  • Hodge WG, Lachaine J, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Morrison A (2008): The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol 92: 7–12

    Article  CAS  PubMed  Google Scholar 

  • Holz F, Martini B (2007): Pegaptanib. Intravitreale Injektion bei neovaskulärer altersabhängiger Makuladegeneration. Arzneimitteltherapie 25: 47–50

    CAS  Google Scholar 

  • Hwang DG, Schanzlin DJ, Rotberg MH, Foulks G, Raizman MB; Levofloxacin Bacterial Conjunctivitis Place-controlled Study Group (2003): A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 87: 1004–1009

    Article  Google Scholar 

  • Isenberg SJ, Apt L, Valenton M, Del Signore M, Cubillan L, Labrador MA et al (2002): A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol 134: 681–688

    Article  CAS  PubMed  Google Scholar 

  • Jackson WB, Low DE, Dattani D, Whitsitt PF, Leeder RG, MacDougall R (2002): Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol 37: 228–237

    Article  PubMed  Google Scholar 

  • Jansen RM (2013): The off-label use of medication: the latest on the Avastin - Lucentis debacle. Med Law 32: 65–77

    PubMed  Google Scholar 

  • Jiang S, Park C, Barner JC (2014): Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab. J Clin Pharm Ther. 39: 234–239

    Article  CAS  PubMed  Google Scholar 

  • Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al (2002): The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypo- tensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701–713

    Article  PubMed  Google Scholar 

  • Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR; Ocular Hypertension Treatment Study Group (2010): Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthal- mol 128: 276–287

    Google Scholar 

  • Katz LJ (1999): Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 127: 20–26

    Article  CAS  PubMed  Google Scholar 

  • Koss MJ, Eder M, Blumenkranz MS, Klauss V, Ta CN, de Kaspar HM (2007): Wirksamkeit neuer Fluorchinolone gegenüber der bakteriellen Normalflora der Bindehaut. Ophthalmologe 104: 21–27

    Article  CAS  PubMed  Google Scholar 

  • Kowalski RP, Kowalski TA, Shanks RM Romanowski EG, Karenchak LM, Mah FS (2013): In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection. Cornea 32: 830–834

    Article  PubMed Central  PubMed  Google Scholar 

  • Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group (2013): A randomised dou- ble-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Oph- thalmol 97: 266–271

    Google Scholar 

  • Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S; Low-Pressure Glaucoma Study Group (2011): A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 151: 671–681

    Article  Google Scholar 

  • Lai DS, Lue KH, Hsieh JC, Lin KL, Lee HS (2002): The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol 89: 589–598

    Article  CAS  PubMed  Google Scholar 

  • Leung VC, Jin YP, Hatch W, Mammo Z, Trope GE, Buys YM, Macrae WG (2015): The relationship between sociodemographic factors and persistence with topical glaucoma medications. J Glaucoma 24: 69–76

    Article  PubMed  Google Scholar 

  • Lynch SS, Cheng CM (2007): Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 41: 614–625

    Article  CAS  PubMed  Google Scholar 

  • Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group) (2013): Incidence of choroidal neo- vascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120: 2035–2041

    Article  PubMed Central  PubMed  Google Scholar 

  • Mantadakis E, Maraki S, Michailidis L, Gitti Z, Pallikaris IG, Samonis G (2013): Antimicrobial susceptibility of Gram-positive cocci isolated from patients with conjunctivitis and keratitis in Crete, Greece. J Microbiol Immunol Infect 46: 41–47

    Article  CAS  PubMed  Google Scholar 

  • Messmer EM (2012): Bakterielle Konjunktivitis - Update zu Diagnose und Therapie. Klin Monbl Augenheilkd 229: 529–533

    Article  CAS  PubMed  Google Scholar 

  • Musch DC, Gillespie BW, Niziol LM, Lichter PR, Varma R; CIGTS Study Group (2011): Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 118: 1766–1773

    Article  Google Scholar 

  • Nesher R; Israel Glaucoma Screening Group (2014): Prevalence of increased intraocular pressure and optic disk cupping: multicenter glaucoma screening in Israel during the 2009 and 2010 World Glaucoma Weeks. Isr Med Assoc J 16: 483–486

    Google Scholar 

  • Noble S, McTavish D (1995): Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs 50: 1032104–9

    Google Scholar 

  • Nordlund JR, Pasquale LR, Robin AL et al (1995): The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 113: 77–83

    Article  CAS  PubMed  Google Scholar 

  • O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P (1995): Efficacy of ofloxacin vs cefazo- lin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol 113: 1257–1265

    Article  PubMed  Google Scholar 

  • Orden Martinez B, Martinez Ruiz R, Millan Perez R (2004): Bakterielle Konjunktivitis: Prävalenz von Pathogenen und ihre Antibiotikaresistenz [Artikel auf Spanisch]. An Pediatr (Barc) 61: 32–36

    Article  CAS  Google Scholar 

  • Parrish RK, Palmberg P, Sheu WP and the XLT Study Group (2003): A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135: 688–703

    Article  CAS  PubMed  Google Scholar 

  • Parrish RK, Feuer WJ, Schiffman JC, Lichter PR, Musch DC; CIGTS Optic Disc Study Group (2009): Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. Am J Ophthalmol 147: 717–724

    Article  Google Scholar 

  • Perry CM, McGavin JK, Culy CR, Ibbotson T (2003): Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 20: 597–630

    Article  CAS  PubMed  Google Scholar 

  • Pfeiffer N (2005): Ergebnisse der "Ocular hypertension treatment study" (OHTS) Ophthalmologe 102: 230–234

    Article  CAS  PubMed  Google Scholar 

  • Pfeiffer N, TATS (Travatan Adjunctive Treatment Study) group (2011): Timolol versus brinzola- mide added to travoprost in glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol 249: 1065–1071

    Article  Google Scholar 

  • Quigley HA (1996): Number of people with glaucoma worldwide. Brit J Ophthalmol 80: 38939–3

    Article  Google Scholar 

  • Rachwalik D, Pleyer U (2015): Bakterielle Keratitis. Klin Monbl Augenheilkd 232: 738–744

    Article  CAS  PubMed  Google Scholar 

  • Ravinet E, Mermoud A, Brignoli R (2003): Four years later: a clinical update on latanoprost. Eur J Ophthalmol 13: 162–175

    CAS  PubMed  Google Scholar 

  • Ray KJ, Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Glidden DV, Oldenburg CE,

    Google Scholar 

  • Sun CQ, Zegans ME, McLeod SD, Acharya NR, Lietman TM (2014): Early addition of topical corticosteroids in the treatment of bacterial keratitis. JAMA Ophthalmol 132: 737–741

    Article  PubMed Central  PubMed  Google Scholar 

  • Rietveld RP, ter Riet G, Bindels PJ, Sloos JH, van Weert HC (2004): Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. Brit med J 329: 206–210

    Google Scholar 

  • Rose P (2007): Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother 8: 1903–1921

    Article  CAS  PubMed  Google Scholar 

  • Rosenfeld PJ (2011): Bevacizumab versus Ranibizumab - The Verdict. New Engl J Med 364: 1966–1967

    Article  CAS  PubMed  Google Scholar 

  • Sabel BA, Gudlin J (2014): Vision restoration training for glaucoma: a randomized clinical trial. JAMA Ophthalmol 132: 381–389

    Article  PubMed  Google Scholar 

  • Schachar RA, Raber S, Courtney R, Zhang M (2011): A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res 36: 809–817

    Article  CAS  PubMed  Google Scholar 

  • Schalnus R (2003): Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthal- mologica 217: 89–98

    Google Scholar 

  • Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS (2014): Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121: 193–201

    Article  PubMed  Google Scholar 

  • Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT; Levofloxacin Bacterial Conjunctivitis Active Control Study Group (2003): A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 110: 457–465

    Article  Google Scholar 

  • Sena DF, Ramchand K, Lindsley K (2010): Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2010: CD00653–9

    Google Scholar 

  • Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U (2012): Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2012: CD001211 Shiuey Y, Ambati BK, Adamis AP (2000): A randomized, double-masked trial of topical ketoro- lac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology 107: 15121517

    Google Scholar 

  • Sorensen SJ, Abel SR (1996): Comparison of the ocular beta-blockers. Ann Pharmacother 30: 43–54

    CAS  PubMed  Google Scholar 

  • Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group (2012): Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol. 130: 143–150

    Article  CAS  PubMed  Google Scholar 

  • Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, O'Brien KS, Glidden DV, Ray KJ, Oldenburg CE, Zegans ME, Whitcher JP, McLeod SD, Porco TC, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group (2014): The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial. Am J Ophthalmol. 157: 327-333.e3

    Google Scholar 

  • Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW (2014): Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 121: 936–945

    Article  PubMed Central  PubMed  Google Scholar 

  • Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A (2009): Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 148: 875-882.e1

    Google Scholar 

  • Szaflik J, Szaflik JP, Kaminska A; Levofloxacin Bacterial Conjunctivitis Dosage Study Group (2009): Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Eur J Ophthalmol 19: 1–9

    Google Scholar 

  • Tamm ER, Schmetterer L, Grehn F (2013): Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper. Cell Tissue Res 353: 347–354

    Article  PubMed  Google Scholar 

  • Uusitalo H, Pillunat LE, Ropo A (2010): Efficacy and safety of tafluprost 0.0015% versus latano- prost 0.005% eye drops in open angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol 88: 12–19

    Article  CAS  PubMed  Google Scholar 

  • van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH (2005): Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112: 1177–1185

    Article  Google Scholar 

  • Wand M, Gilbert CM, Liesegang TJ (1999): Latanoprost and herpes simplex keratitis. Am J Ophthalmol 127: 602–604

    Article  CAS  PubMed  Google Scholar 

  • Wang SK, Chang RT (2014): An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol 8: 883–890

    PubMed Central  CAS  PubMed  Google Scholar 

  • Watson PG, Barnett MF, Parker V, Haybittle J (2001): A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol 85: 962–968

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Webers CA, Beckers HJ, Nuijts RM, Schouten JS (2008): Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 25: 729–759

    Article  CAS  PubMed  Google Scholar 

  • Weinreb RN, Khaw PT (2004): Primary open-angle glaucoma. Lancet 363: 1711–1720

    Article  PubMed  Google Scholar 

  • Whitson JT (2007): Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother 8: 3237–3249

    Article  CAS  PubMed  Google Scholar 

  • Wright M, Butt Z, McIlwaine G, Fleck B (1997): Comparison of the efficacy of diclofenac and betamethasone following strabismus surgery. Brit J Ophthalmol 81: 299–301

    Article  CAS  Google Scholar 

  • Yildirim N, Sahin A, Gultekin S (2008): The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glau- coma 17: 36–39

    Google Scholar 

Download references

Authors
  1. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2015 Springer-Verlag Berlin Heidelberg

    About this chapter

    Cite this chapter

    Lohse, M. (2015). Ophthalmika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_35

    Download citation

    • DOI: https://doi.org/10.1007/978-3-662-47186-9_35

    • Publisher Name: Springer, Berlin, Heidelberg

    • Print ISBN: 978-3-662-47185-2

    • Online ISBN: 978-3-662-47186-9

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation